{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T14:39:09Z","timestamp":1787495949543,"version":"build-2736575974"},"reference-count":180,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82270969"],"award-info":[{"award-number":["82270969"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.critrevonc.2026.105339","type":"journal-article","created":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T07:25:38Z","timestamp":1776237938000},"page":"105339","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Alternative splicing of immune checkpoints: Classifications, mechanisms, and therapeutic implications for overcoming immune checkpoint blockade resistance"],"prefix":"10.1016","volume":"223","author":[{"given":"Ping","family":"Lu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jihua","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.critrevonc.2026.105339_bib1","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1089\/oli.2009.0215","article-title":"Exonic sequences provide better targets for antisense oligonucleotides than splice site sequences in the modulation of Duchenne muscular dystrophy splicing","volume":"20","author":"Aartsma-Rus","year":"2010","journal-title":"Oligonucleotides"},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105339_bib2","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1007\/s10555-023-10099-x","article-title":"Oral delivery of RNAi for cancer therapy","volume":"42","author":"Afrin","year":"2023","journal-title":"Cancer Metastasis Rev."},{"key":"10.1016\/j.critrevonc.2026.105339_bib3","doi-asserted-by":"crossref","first-page":"435","DOI":"10.3762\/bjnano.16.34","article-title":"Synthetic-polymer-assisted antisense oligonucleotide delivery: targeted approaches for precision disease treatment","volume":"16","author":"Alvarez","year":"2025","journal-title":"Beilstein J. Nanotechnol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105339_bib4","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s40364-024-00556-2","article-title":"BTLA biology in cancer: from bench discoveries to clinical potentials","volume":"12","author":"Andrzejczak","year":"2024","journal-title":"Biomark. Res."},{"key":"10.1016\/j.critrevonc.2026.105339_bib5","article-title":"Soluble CTLA-4 - A confounding factor in CTLA-4 based checkpoint immunotherapy in cancer","volume":"10","author":"Azimnasab-Sorkhabi","year":"2024","journal-title":"Immunol. Lett."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105339_bib6","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1007\/s13577-023-00893-8","article-title":"Cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) as an undetermined tool in tumor cells","volume":"36","author":"Azimnasab-Sorkhabi","year":"2023","journal-title":"Hum. Cell"},{"issue":"6114","key":"10.1016\/j.critrevonc.2026.105339_bib7","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1126\/science.1230612","article-title":"The evolutionary landscape of alternative splicing in vertebrate species","volume":"338","author":"Barbosa-Morais","year":"2012","journal-title":"Science"},{"issue":"11","key":"10.1016\/j.critrevonc.2026.105339_bib8","doi-asserted-by":"crossref","first-page":"2952","DOI":"10.1158\/0008-5472.CAN-16-1638","article-title":"Tumor-localized secretion of soluble PD1 enhances oncolytic virotherapy","volume":"77","author":"Bartee","year":"2017","journal-title":"Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105339_bib9","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1386993","article-title":"Deciphering the role of alternative splicing in neoplastic diseases for immune-oncological therapies","volume":"15","author":"Bauer","year":"2024","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105339_bib10","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/S0006-291X(03)01560-2","article-title":"Identification of secreted CD155 isoforms","volume":"309","author":"Baury","year":"2003","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"8","key":"10.1016\/j.critrevonc.2026.105339_bib11","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1038\/s41571-020-0350-x","article-title":"Roles and mechanisms of alternative splicing in cancer - implications for care","volume":"17","author":"Bonnal","year":"2020","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"11","key":"10.1016\/j.critrevonc.2026.105339_bib12","doi-asserted-by":"crossref","first-page":"5038","DOI":"10.4049\/jimmunol.153.11.5038","article-title":"Characterization of the murine B7-1 genomic locus reveals an additional exon encoding an alternative cytoplasmic domain and a chromosomal location of chromosome 16, band B5","volume":"153","author":"Borriello","year":"1994","journal-title":"J. Immunol."},{"key":"10.1016\/j.critrevonc.2026.105339_bib13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.virusres.2017.09.001","article-title":"Poliovirus Receptor: more than a simple viral receptor","volume":"242","author":"Bowers","year":"2017","journal-title":"Virus Res."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105339_bib14","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1038\/s41568-022-00541-7","article-title":"RNA splicing dysregulation and the hallmarks of cancer","volume":"23","author":"Bradley","year":"2023","journal-title":"Nat. Rev. Cancer"},{"issue":"10","key":"10.1016\/j.critrevonc.2026.105339_bib15","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1158\/2326-6066.CIR-16-0063","article-title":"Correlation of PD-L1 surface expression on leukemia cells with the ratio of PD-L1 mRNA variants and with electrophoretic mobility","volume":"4","author":"Brodsk\u00e1","year":"2016","journal-title":"Cancer Immunol. Res."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105339_bib16","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1002\/1521-4141(200101)31:1<118::AID-IMMU118>3.0.CO;2-X","article-title":"Selective silencing of full-length CD80 but not IgV-CD80 leads to impaired clonal deletion of self-reactive T cells and altered regulation of immune responses","volume":"31","author":"Bugeon","year":"2001","journal-title":"Eur. J. Immunol."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105339_bib17","article-title":"Soluble immune checkpoint molecules: serum markers for cancer diagnosis and prognosis","volume":"2","author":"Chakrabarti","year":"2019","journal-title":"Cancer Rep."},{"issue":"16","key":"10.1016\/j.critrevonc.2026.105339_bib18","article-title":"Expression of alternatively spliced PD-L1 RNA with skipping of transmembrane domain","volume":"42","author":"Charifa","year":"2024","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105339_bib19","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1016\/j.immuni.2012.07.016","article-title":"The short isoform of the CEACAM1 receptor in intestinal T cells regulates mucosal immunity and homeostasis via Tfh cell induction","volume":"37","author":"Chen","year":"2012","journal-title":"Immunity"},{"issue":"3-4","key":"10.1016\/j.critrevonc.2026.105339_bib20","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.vetimm.2008.07.009","article-title":"Cloning, expression and characterization of monkey (Macaca fascicularis) CD137","volume":"126","author":"Chen","year":"2008","journal-title":"Vet. Immunol. Immunopathol."},{"issue":"10","key":"10.1016\/j.critrevonc.2026.105339_bib21","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0076965","article-title":"Characterization of a soluble B7-H3 (sB7-H3) spliced from the intron and analysis of sB7-H3 in the sera of patients with hepatocellular carcinoma","volume":"8","author":"Chen","year":"2013","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105339_bib22","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/j.imbio.2019.02.009","article-title":"Interferon-\u03b3 upregulates \u039442PD1 expression on human monocytes via the PI3K\/AKT pathway","volume":"224","author":"Cheng","year":"2019","journal-title":"Immunobiology"},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105339_bib23","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.3390\/cancers15061696","article-title":"A novel role for the soluble isoform of CTLA-4 in normal, dysplastic and neoplastic oral and oropharyngeal epithelia","volume":"15","author":"Clare","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.critrevonc.2026.105339_bib24","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2017.1328336","article-title":"CEACAM1 as a multi-purpose target for cancer immunotherapy","author":"Dankner","year":"2017","journal-title":"Oncoimmunology 6(7) e1328336"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105339_bib25","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1111\/nph.12238","article-title":"Features of evolutionarily conserved alternative splicing events between Brassica and Arabidopsis","volume":"199","author":"Darracq","year":"2013","journal-title":"N. Phytol."},{"issue":"7","key":"10.1016\/j.critrevonc.2026.105339_bib26","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1517\/14712598.2015.1044433","article-title":"Arming oncolytic viruses to leverage antitumor immunity","volume":"15","author":"de Gruijl","year":"2015","journal-title":"Expert Opin. Biol. Ther."},{"issue":"18","key":"10.1016\/j.critrevonc.2026.105339_bib27","doi-asserted-by":"crossref","first-page":"16039","DOI":"10.1074\/jbc.M110.204057","article-title":"Mechanistic control of carcinoembryonic antigen-related cell adhesion molecule-1 (CEACAM1) splice isoforms by the heterogeneous nuclear ribonuclear proteins hnRNP L, hnRNP A1, and hnRNP M","volume":"286","author":"Dery","year":"2011","journal-title":"J. Biol. Chem."},{"issue":"707","key":"10.1016\/j.critrevonc.2026.105339_bib28","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.adf2059","article-title":"Alternative splicing of CEACAM1 by hypoxia-inducible factor-1\u03b1 enhances tolerance to hepatic ischemia in mice and humans","volume":"15","author":"Dery","year":"2023","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.critrevonc.2026.105339_bib29","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1186\/1476-4598-13-64","article-title":"IRF-1 regulates alternative mRNA splicing of carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1) in breast epithelial cells generating an immunoreceptor tyrosine-based inhibition motif (ITIM) containing isoform","volume":"13","author":"Dery","year":"2014","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105339_bib30","doi-asserted-by":"crossref","DOI":"10.1111\/eci.14350","article-title":"Mechanism and function of CEACAM1 splice isoforms","volume":"54","author":"Dery","year":"2024","journal-title":"Eur. J. Clin. Invest"},{"issue":"24","key":"10.1016\/j.critrevonc.2026.105339_bib31","doi-asserted-by":"crossref","first-page":"9277","DOI":"10.1074\/jbc.RA117.001507","article-title":"Interferon regulatory factor 1 and a variant of heterogeneous nuclear ribonucleoprotein L coordinately silence the gene for adhesion protein CEACAM1","volume":"293","author":"Dery","year":"2018","journal-title":"J. Biol. Chem."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105339_bib32","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/S0198-8859(01)00354-8","article-title":"A novel CD28 mRNA variant and simultaneous presence of various CD28 mRNA isoforms in human T lymphocytes","volume":"63","author":"Deshpande","year":"2002","journal-title":"Hum. Immunol."},{"issue":"9","key":"10.1016\/j.critrevonc.2026.105339_bib33","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1097\/CJI.0000000000000439","article-title":"An extended PD-L2 cytoplasmic domain results from alternative splicing in NSCLC cells","volume":"45","author":"Dietz","year":"2022","journal-title":"J. Immunother."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105339_bib34","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.immuni.2024.01.019","article-title":"Lactate modulates RNA splicing to promote CTLA-4 expression in tumor-infiltrating regulatory T cells","volume":"57","author":"Ding","year":"2024","journal-title":"Immunity"},{"issue":"12","key":"10.1016\/j.critrevonc.2026.105339_bib35","doi-asserted-by":"crossref","first-page":"4065","DOI":"10.1007\/s00262-023-03543-y","article-title":"An alternatively spliced PD-L1 isoform PD-L1\u22063, and PD-L2 expression in breast cancers: implications for eligibility scoring and immunotherapy response","volume":"72","author":"Dioken","year":"2023","journal-title":"Cancer Immunol. Immunother."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105339_bib36","doi-asserted-by":"crossref","first-page":"2973","DOI":"10.1038\/s41467-020-16806-4","article-title":"CRISPR artificial splicing factors","volume":"11","author":"Du","year":"2020","journal-title":"Nat. Commun."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105339_bib37","doi-asserted-by":"crossref","DOI":"10.1111\/cns.14489","article-title":"A TGF-\u03b2 signaling-related lncRNA signature for prediction of glioma prognosis, immune microenvironment, and immunotherapy response","volume":"30","author":"Duan","year":"2024","journal-title":"CNS Neurosci. Ther."},{"issue":"7","key":"10.1016\/j.critrevonc.2026.105339_bib38","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1038\/nrc.2016.51","article-title":"RNA splicing factors as oncoproteins and tumour suppressors","volume":"16","author":"Dvinge","year":"2016","journal-title":"Nat. Rev. Cancer"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105339_bib39","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1007\/s00280-025-04848-8","article-title":"Mechanisms of resistance to antibody-drug conjugates in cancer: molecular barriers and pharmacological solutions","volume":"95","author":"Eltaib","year":"2025","journal-title":"Cancer Chemother. Pharm."},{"issue":"12","key":"10.1016\/j.critrevonc.2026.105339_bib40","doi-asserted-by":"crossref","first-page":"6340","DOI":"10.4049\/jimmunol.164.12.6340","article-title":"Primary structure and functional characterization of a soluble, alternatively spliced form of B7-1","volume":"164","author":"Faas","year":"2000","journal-title":"J. Immunol."},{"key":"10.1016\/j.critrevonc.2026.105339_bib41","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2023.101801","article-title":"B7-H3\/CD276 and small-cell lung cancer: What's new?","volume":"39","author":"Fabrizio","year":"2024","journal-title":"Transl. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105339_bib42","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1038\/s41598-022-06430-1","article-title":"Dual-sgRNA CRISPR\/Cas9 knockout of PD-L1 in human U87 glioblastoma tumor cells inhibits proliferation, invasion, and tumor-associated macrophage polarization","volume":"12","author":"Fierro","year":"2022","journal-title":"Sci. Rep."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105339_bib43","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1093\/nar\/gkaa1260","article-title":"Targeting alternative splicing by RNAi: from the differential impact on splice variants to triggering artificial pre-mRNA splicing","volume":"49","author":"Fuchs","year":"2021","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.critrevonc.2026.105339_bib44","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/1476-4598-7-46","article-title":"Altered splicing of CEACAM1 in breast cancer: identification of regulatory sequences that control splicing of CEACAM1 into long or short cytoplasmic domain isoforms","volume":"7","author":"Gaur","year":"2008","journal-title":"Mol. Cancer"},{"issue":"10","key":"10.1016\/j.critrevonc.2026.105339_bib45","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1089\/107999001753238042","article-title":"IFN-beta1a modulates the expression of CTLA-4 and CD28 splice variants in human mononuclear cells: induction of soluble isoforms","volume":"21","author":"Giorelli","year":"2001","journal-title":"J. Interferon Cytokine Res."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105339_bib46","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003532","article-title":"Soluble CD137 as a dynamic biomarker to monitor agonist CD137 immunotherapies","volume":"10","author":"Glez-Vaz","year":"2022","journal-title":"J. Immunother. Cancer"},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105339_bib47","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1084\/jem.20180870","article-title":"Secreted PD-L1 variants mediate resistance to PD-L1 blockade therapy in non\u2013small cell lung cancer","volume":"216","author":"Gong","year":"2019","journal-title":"J. Exp. Med."},{"issue":"12","key":"10.1016\/j.critrevonc.2026.105339_bib48","doi-asserted-by":"crossref","first-page":"3758","DOI":"10.1002\/eji.201444574","article-title":"UPR decreases CD226 ligand CD155 expression and sensitivity to NK cell-mediated cytotoxicity in hepatoma cells","volume":"44","author":"Gong","year":"2014","journal-title":"Eur. J. Immunol."},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105339_bib49","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1002\/ijc.33610","article-title":"Serum levels of soluble B and T lymphocyte attenuator predict overall survival in patients undergoing immune checkpoint inhibitor therapy for solid malignancies","volume":"149","author":"Gorgulho","year":"2021","journal-title":"Int. J. Cancer"},{"issue":"8","key":"10.1016\/j.critrevonc.2026.105339_bib50","doi-asserted-by":"crossref","first-page":"4660","DOI":"10.1097\/JS9.0000000000001479","article-title":"Comparative investigation of neoadjuvant immunotherapy versus adjuvant immunotherapy in perioperative patients with cancer: a global-scale, cross-sectional, and large-sample informatics study","volume":"110","author":"Guo","year":"2024","journal-title":"Int. J. Surg."},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105339_bib51","doi-asserted-by":"crossref","first-page":"2829","DOI":"10.4049\/jimmunol.1202777","article-title":"Soluble CD80 restores T cell activation and overcomes tumor cell programmed death ligand 1\u2013mediated immune suppression","volume":"191","author":"Haile","year":"2013","journal-title":"J. Immunol."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105339_bib52","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1006\/bbrc.1999.1040","article-title":"hnRNP A2 and hnRNP L bind the 3\u2032UTR of glucose transporter 1 mRNA and exist as a complex in vivo","volume":"261","author":"Hamilton","year":"1999","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"12","key":"10.1016\/j.critrevonc.2026.105339_bib53","doi-asserted-by":"crossref","first-page":"7842","DOI":"10.4049\/jimmunol.0804379","article-title":"Soluble B and T lymphocyte attenuator possesses antitumor effects and facilitates heat shock protein 70 vaccine-triggered antitumor immunity against a murine TC-1 cervical cancer model in vivo","volume":"183","author":"Han","year":"2009","journal-title":"J. Immunol."},{"issue":"10","key":"10.1016\/j.critrevonc.2026.105339_bib54","doi-asserted-by":"crossref","first-page":"5931","DOI":"10.4049\/jimmunol.172.10.5931","article-title":"An inhibitory Ig superfamily protein expressed by lymphocytes and APCs is also an early marker of thymocyte positive selection1","volume":"172","author":"Han","year":"2004","journal-title":"J. Immunol."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105339_bib55","doi-asserted-by":"crossref","first-page":"242","DOI":"10.4274\/balkanmedj.galenos.2025.2025-1-129","article-title":"Potential roles of serum exosomal CD155 and its impact on NK cell immunosuppression in hepatocellular carcinoma","volume":"42","author":"Han","year":"2025","journal-title":"Balk. Med. J."},{"issue":"12","key":"10.1016\/j.critrevonc.2026.105339_bib56","doi-asserted-by":"crossref","first-page":"17524","DOI":"10.1021\/acsnano.0c08022","article-title":"Beyond blocking: engineering RNAi-mediated targeted immune checkpoint nanoblocker enables t-cell-independent cancer treatment","volume":"14","author":"Han","year":"2020","journal-title":"ACS Nano"},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105339_bib57","doi-asserted-by":"crossref","first-page":"2138","DOI":"10.1182\/blood.V99.6.2138","article-title":"A novel costimulatory signaling in human T lymphocytes by a splice variant of CD28","volume":"99","author":"Hanawa","year":"2002","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105339_bib58","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1007\/s00262-018-2284-z","article-title":"Identification and characterization of an alternative cancer-derived PD-L1 splice variant","volume":"68","author":"Hassounah","year":"2019","journal-title":"Cancer Immunol. Immunother."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105339_bib59","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1111\/j.1745-7254.2005.00086.x","article-title":"Identification of a novel splice variant of human PD-L1 mRNA encoding an isoform-lacking Igv-like domain","volume":"26","author":"He","year":"2005","journal-title":"Acta Pharmacol. Sin."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105339_bib60","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.immuni.2019.12.011","article-title":"Top 10 challenges in cancer immunotherapy","volume":"52","author":"Hegde","year":"2020","journal-title":"Immunity"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105339_bib61","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s40246-022-00419-7","article-title":"rs2013278 in the multiple immunological-trait susceptibility locus CD28 regulates the production of non-functional splicing isoforms","volume":"16","author":"Hitomi","year":"2022","journal-title":"Hum. Genom."},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105339_bib62","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1038\/sj.leu.2402466","article-title":"Human plasma contains a soluble form of CD86 which is present at elevated levels in some leukaemia patients","volume":"16","author":"Hock","year":"2002","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105339_bib63","doi-asserted-by":"crossref","DOI":"10.1093\/bib\/bbaa176","article-title":"Expression profile of immune checkpoint genes and their roles in predicting immunotherapy response","volume":"22","author":"Hu","year":"2021","journal-title":"Brief. Bioinform"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105339_bib64","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s40164-025-00627-6","article-title":"Post-translational modifications of immune checkpoints: unlocking new potentials in cancer immunotherapy","volume":"14","author":"Hu","year":"2025","journal-title":"Exp. Hematol. Oncol."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105339_bib65","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1002\/art.37790","article-title":"Brief report: increased expression of a short splice variant of CTLA-4 exacerbates lupus in MRL\/lpr mice","volume":"65","author":"Ichinose","year":"2013","journal-title":"Arthritis Rheum."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105339_bib66","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1007\/s12282-019-00999-8","article-title":"High expression of soluble CD155 in estrogen receptor-negative breast cancer","volume":"27","author":"Iguchi-Manaka","year":"2020","journal-title":"Breast Cancer"},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105339_bib67","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0152982","article-title":"Increased soluble CD155 in the serum of cancer patients","volume":"11","author":"Iguchi-Manaka","year":"2016","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105339_bib68","doi-asserted-by":"crossref","first-page":"582","DOI":"10.4049\/jimmunol.157.2.582","article-title":"The role of the B7-1a molecule, an alternatively spliced form of murine B7-1 (CD80), on T cell activation","volume":"157","author":"Inobe","year":"1996","journal-title":"J. Immunol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105339_bib69","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/JID.2015.404","article-title":"Melanoma cells control antimelanoma CTL responses via interaction between TIGIT and CD155 in the effector phase","volume":"136","author":"Inozume","year":"2016","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.critrevonc.2026.105339_bib70","doi-asserted-by":"crossref","first-page":"2566","DOI":"10.3389\/fimmu.2019.02566","article-title":"Soluble CD137 ameliorates acute type 1 diabetes by inducing T cell anergy","volume":"10","author":"Itoh","year":"2019","journal-title":"Front. Immunol."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105339_bib71","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/S1074-7613(00)00030-3","article-title":"Soluble CD86 is a costimulatory molecule for human T lymphocytes","volume":"13","author":"Jeannin","year":"2000","journal-title":"Immunity"},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105339_bib72","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1038\/s41568-021-00339-z","article-title":"Antigen presentation in cancer: insights into tumour immunogenicity and immune evasion","volume":"21","author":"Jhunjhunwala","year":"2021","journal-title":"Nat. Rev. Cancer"},{"issue":"1-2","key":"10.1016\/j.critrevonc.2026.105339_bib73","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.imlet.2013.06.004","article-title":"The splicing factor hnRNP C regulates expression of co-stimulatory molecules CD80 and CD40 in dendritic cells","volume":"153","author":"Jia","year":"2013","journal-title":"Immunol. Lett."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105339_bib74","doi-asserted-by":"crossref","DOI":"10.1002\/jcla.24259","article-title":"High serum soluble CD155 level predicts poor prognosis and correlates with an immunosuppressive tumor microenvironment in hepatocellular carcinoma","volume":"36","author":"Jin","year":"2022","journal-title":"J. Clin. Lab. Anal."},{"key":"10.1016\/j.critrevonc.2026.105339_bib75","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.jaut.2013.09.002","article-title":"Recombinant soluble CD137 prevents type one diabetes in nonobese diabetic mice","volume":"47","author":"Kachapati","year":"2013","journal-title":"J. Autoimmun."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105339_bib76","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.ccell.2018.07.001","article-title":"Comprehensive analysis of alternative splicing across tumors from 8,705 patients","volume":"34","author":"Kahles","year":"2018","journal-title":"Cancer Cell"},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105339_bib77","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1111\/j.1365-3083.2007.02009.x","article-title":"Human Soluble CD80 is generated by alternative splicing, and recombinant soluble CD80 binds to CD28 and CD152 influencing T-cell activation","volume":"66","author":"Kakoulidou","year":"2007","journal-title":"Scand. J. Immunol."},{"issue":"17","key":"10.1016\/j.critrevonc.2026.105339_bib78","doi-asserted-by":"crossref","first-page":"5659","DOI":"10.1093\/nar\/gki834","article-title":"Evolutionarily conserved and diverged alternative splicing events show different expression and functional profiles","volume":"33","author":"Kan","year":"2005","journal-title":"Nucleic Acids Res."},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105339_bib79","doi-asserted-by":"crossref","first-page":"3815","DOI":"10.4049\/jimmunol.180.6.3815","article-title":"A novel B7-2 (CD86) splice variant with a putative negative regulatory role","volume":"180","author":"Kapsogeorgou","year":"2008","journal-title":"J. Immunol."},{"issue":"9","key":"10.1016\/j.critrevonc.2026.105339_bib80","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1038\/s41590-022-01289-w","article-title":"Differences in CD80 and CD86 transendocytosis reveal CD86 as a key target for CTLA-4 immune regulation","volume":"23","author":"Kennedy","year":"2022","journal-title":"Nat. Immunol."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105339_bib81","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.ymthe.2023.11.028","article-title":"Soluble CTLA-4 attenuates T cell activation and modulates anti-tumor immunity","volume":"32","author":"Kennedy","year":"2024","journal-title":"Mol. Ther."},{"key":"10.1016\/j.critrevonc.2026.105339_bib82","article-title":"TGF\u03b22 induces the soluble isoform of CTLA-4 - implications for CTLA-4 based checkpoint inhibitor antibodies in malignant melanoma","volume":"12","author":"Khanolkar","year":"2021","journal-title":"Front. Immunol."},{"issue":"551","key":"10.1016\/j.critrevonc.2026.105339_bib83","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaz5683","article-title":"PRMT5 control of cGAS\/STING and NLRC5 pathways defines melanoma response to antitumor immunity","volume":"12","author":"Kim","year":"2020","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.critrevonc.2026.105339_bib84","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.exphem.2023.01.006","article-title":"The levels of serum soluble CD86 are correlated with the expression of CD86 variant 3 gene and are prognostic indicators in patients with myeloma","volume":"121","author":"Kinoshita","year":"2023","journal-title":"Exp. Hematol."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105339_bib85","article-title":"Applications of the versatile CRISPR-Cas13 RNA targeting system","volume":"13","author":"Kordy\u015b","year":"2022","journal-title":"Wiley Inter. Rev. RNA"},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105339_bib86","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1038\/s41568-021-00431-4","article-title":"Programmed death ligand 1 signals in cancer cells","volume":"22","author":"Kornepati","year":"2022","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105339_bib87","doi-asserted-by":"crossref","DOI":"10.1016\/j.preteyeres.2022.101110","article-title":"RNA-targeting strategies as a platform for ocular gene therapy","volume":"92","author":"Kumar","year":"2023","journal-title":"Prog. Retin. Eye Res."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105339_bib88","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2015.1062967","article-title":"Hypoxia-induced soluble CD137 in malignant cells blocks CD137L-costimulation as an immune escape mechanism","volume":"5","author":"Labiano","year":"2016","journal-title":"Oncoimmunology"},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105339_bib89","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1189\/jlb.0303105","article-title":"Hypoxia reduces CD80 expression on monocytes but enhances their LPS-stimulated TNF-alpha secretion","volume":"74","author":"Lahat","year":"2003","journal-title":"J. Leukoc. Biol."},{"issue":"24","key":"10.1016\/j.critrevonc.2026.105339_bib90","doi-asserted-by":"crossref","first-page":"2844","DOI":"10.3390\/cells12242844","article-title":"Trans-regulation of alternative PD-L1 mRNA processing by CDK12 in non-small-cell lung cancer cells","volume":"12","author":"Larsen","year":"2023","journal-title":"Cells"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105339_bib91","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.ymthe.2024.12.010","article-title":"CD137-expressing regulatory T cells in cancer and autoimmune diseases","volume":"33","author":"Lee","year":"2025","journal-title":"Mol. Ther."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105339_bib92","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s12865-021-00422-y","article-title":"Soluble cytotoxic T-lymphocyte-associated antigen 4 (sCTLA-4) as a potential biomarker for diagnosis and evaluation of the prognosis in Glioma","volume":"22","author":"Liu","year":"2021","journal-title":"BMC Immunol."},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105339_bib93","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1002\/JLB.2MR1119-224R","article-title":"The relevance of soluble CD137 in the regulation of immune responses and for immunotherapeutic intervention","volume":"107","author":"Luu","year":"2020","journal-title":"J. Leukoc. Biol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105339_bib94","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s13046-025-03279-w","article-title":"Targeting RNA splicing modulation: new perspectives for anticancer strategy?","volume":"44","author":"Lv","year":"2025","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105339_bib95","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1006\/bbrc.2000.4102","article-title":"Identification of an alternatively spliced variant of human CD86 mRNA","volume":"280","author":"Magistrelli","year":"2001","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105339_bib96","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1006\/bbrc.1999.0725","article-title":"Identification of three alternatively spliced variants of human CD28 mRNA","volume":"259","author":"Magistrelli","year":"1999","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"11","key":"10.1016\/j.critrevonc.2026.105339_bib97","doi-asserted-by":"crossref","first-page":"3596","DOI":"10.1002\/(SICI)1521-4141(199911)29:11<3596::AID-IMMU3596>3.0.CO;2-Y","article-title":"A soluble form of CTLA-4 generated by alternative splicing is expressed by nonstimulated human T cells","volume":"29","author":"Magistrelli","year":"1999","journal-title":"Eur. J. Immunol."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105339_bib98","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1007\/s00262-018-2282-1","article-title":"A secreted PD-L1 splice variant that covalently dimerizes and mediates immunosuppression","volume":"68","author":"Mahoney","year":"2019","journal-title":"Cancer Immunol. Immunother."},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105339_bib99","doi-asserted-by":"crossref","DOI":"10.1002\/bies.202400202","article-title":"Gene duplication and alternative splicing as evolutionary drivers of proteome specialization","volume":"47","author":"Mantica","year":"2025","journal-title":"Bioessays"},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105339_bib100","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1038\/s41580-022-00545-z","article-title":"The physiology of alternative splicing","volume":"24","author":"Marasco","year":"2023","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.critrevonc.2026.105339_bib101","doi-asserted-by":"crossref","first-page":"3044","DOI":"10.1200\/JCO.2016.34.15_suppl.3044","article-title":"Inhibition of the novel immune checkpoint CEACAM1 to enhance anti-tumor immunological activity","volume":"34","author":"Markel","year":"2016","journal-title":"J. Clin. Oncol."},{"issue":"7","key":"10.1016\/j.critrevonc.2026.105339_bib102","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1101\/gr.186585.114","article-title":"Unmasking alternative splicing inside protein-coding exons defines exitrons and their role in proteome plasticity","volume":"25","author":"Marquez","year":"2015","journal-title":"Genome Res."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105339_bib103","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1111\/imr.12047","article-title":"Control of alternative splicing in immune responses: many regulators, many predictions, much still to learn","volume":"253","author":"Martinez","year":"2013","journal-title":"Immunol. Rev."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105339_bib104","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1186\/s13018-022-03283-2","article-title":"The role of soluble CD80 in patients with soft tissue tumors","volume":"17","author":"Matsuyama","year":"2022","journal-title":"J. Orthop. Surg. Res."},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105339_bib105","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1006\/cyto.1999.0623","article-title":"Expression of soluble CD137 correlates with activation-induced cell death of lymphocytes","volume":"12","author":"Michel","year":"2000","journal-title":"Cytokine"},{"issue":"7","key":"10.1016\/j.critrevonc.2026.105339_bib106","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1084\/jem.20031705","article-title":"The modulation of CD40 ligand signaling by transmembrane CD28 splice variant in human T cells","volume":"199","author":"Mikolajczak","year":"2004","journal-title":"J. Exp. Med."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105339_bib107","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1186\/s13059-017-1237-8","article-title":"CRISPR\/Cas9-mediated genome editing induces exon skipping by alternative splicing or exon deletion","volume":"18","author":"Mou","year":"2017","journal-title":"Genome Biol."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105339_bib108","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1089\/nat.2013.0449","article-title":"Alternative splice forms of CTLA-4 induced by antisense mediated splice-switching influences autoimmune diabetes susceptibility in NOD mice","volume":"24","author":"Mourich","year":"2014","journal-title":"Nucleic Acid. Ther."},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105339_bib109","doi-asserted-by":"crossref","first-page":"2729","DOI":"10.1007\/s00018-020-03727-0","article-title":"Hypoxia-induced alternative splicing in human diseases: the pledge, the turn, and the prestige","volume":"78","author":"Natua","year":"2021","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.critrevonc.2026.105339_bib110","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.50256","article-title":"Soluble PD-L1 generated by endogenous retroelement exaptation is a receptor antagonist","volume":"8","author":"Ng","year":"2019","journal-title":"Elife"},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105339_bib111","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.cellimm.2005.07.007","article-title":"Alternative splice variants of the human PD-1 gene","volume":"235","author":"Nielsen","year":"2005","journal-title":"Cell. Immunol."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105339_bib112","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1038\/nbt.3427","article-title":"Antisense oligonucleotide-directed inhibition of nonsense-mediated mRNA decay","volume":"34","author":"Nomakuchi","year":"2016","journal-title":"Nat. Biotechnol."},{"issue":"19","key":"10.1016\/j.critrevonc.2026.105339_bib113","doi-asserted-by":"crossref","first-page":"11926","DOI":"10.1093\/nar\/gkae682","article-title":"A CRISPR-dCas13 RNA-editing tool to study alternative splicing","volume":"52","author":"N\u00fa\u00f1ez-\u00c1lvarez","year":"2024","journal-title":"Nucleic Acids Res."},{"issue":"10","key":"10.1016\/j.critrevonc.2026.105339_bib114","doi-asserted-by":"crossref","first-page":"5015","DOI":"10.4049\/jimmunol.164.10.5015","article-title":"Cutting edge: a soluble form of CTLA-4 in patients with autoimmune thyroid disease","volume":"164","author":"Oaks","year":"2000","journal-title":"J. Immunol."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105339_bib115","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1006\/cimm.2000.1649","article-title":"A native soluble form of CTLA-4","volume":"201","author":"Oaks","year":"2000","journal-title":"Cell. Immunol."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105339_bib116","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1084\/jem.20191290","article-title":"Tumor-derived soluble CD155 inhibits DNAM-1-mediated antitumor activity of natural killer cells","volume":"217","author":"Okumura","year":"2020","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.critrevonc.2026.105339_bib117","doi-asserted-by":"crossref","DOI":"10.1016\/j.cis.2025.103497","article-title":"Comprehensive strategies for constructing efficient CRISPR\/Cas based cancer therapy: target gene selection, sgRNA optimization, delivery methods and evaluation","volume":"341","author":"Paranthaman","year":"2025","journal-title":"Adv. Colloid Interface Sci."},{"issue":"43","key":"10.1016\/j.critrevonc.2026.105339_bib118","doi-asserted-by":"crossref","first-page":"15544","DOI":"10.1073\/pnas.1416074111","article-title":"Characterization of HPV and host genome interactions in primary head and neck cancers","volume":"111","author":"Parfenov","year":"2014","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105339_bib119","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1186\/s13046-024-03074-z","article-title":"Soluble immune checkpoints: implications for cancer prognosis and response to immune checkpoint therapy and conventional therapies","volume":"43","author":"Pitts","year":"2024","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105339_bib120","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1186\/s13059-021-02331-0","article-title":"PD-L1 lncRNA splice isoform promotes lung adenocarcinoma progression via enhancing c-Myc activity","volume":"22","author":"Qu","year":"2021","journal-title":"Genome Biol."},{"issue":"6721","key":"10.1016\/j.critrevonc.2026.105339_bib121","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1126\/science.adn8105","article-title":"Transcriptome-wide splicing network reveals specialized regulatory functions of the core spliceosome","volume":"386","author":"Rogalska","year":"2024","journal-title":"Science"},{"key":"10.1016\/j.critrevonc.2026.105339_bib122","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2024.1325558","article-title":"Recombinant Newcastle disease viruses expressing immunological checkpoint inhibitors induce a pro-inflammatory state and enhance tumor-specific immune responses in two murine models of cancer","volume":"15","author":"Santry","year":"2024","journal-title":"Front. Microbiol."},{"key":"10.1016\/j.critrevonc.2026.105339_bib123","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2020.100728","article-title":"The role of alternative splicing in cancer: from oncogenesis to drug resistance","volume":"53","author":"Sciarrillo","year":"2020","journal-title":"Drug Resist. Updat."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105339_bib124","doi-asserted-by":"crossref","first-page":"6984","DOI":"10.1038\/s41598-019-43068-y","article-title":"RGMB enhances the suppressive activity of the monomeric secreted form of CTLA-4","volume":"9","author":"Sekiya","year":"2019","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105339_bib125","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1007\/s11033-024-09949-w","article-title":"Decoding the genetic influence of CT60 non-coding polymorphism in CTLA-4 gene and sCTLA-4 biomarker with rheumatoid arthritis in the Indian population","volume":"51","author":"Shamala","year":"2024","journal-title":"Mol. Biol. Rep."},{"issue":"15","key":"10.1016\/j.critrevonc.2026.105339_bib126","doi-asserted-by":"crossref","first-page":"3990","DOI":"10.1016\/j.molimm.2008.05.028","article-title":"Characterisation of soluble murine CD137 and its association with systemic lupus","volume":"45","author":"Shao","year":"2008","journal-title":"Mol. Immunol."},{"key":"10.1016\/j.critrevonc.2026.105339_bib127","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1350208","article-title":"Redefining the battle against colorectal cancer: a comprehensive review of emerging immunotherapies and their clinical efficacy","volume":"15","author":"Shebbo","year":"2024","journal-title":"Front. Immunol."},{"issue":"14","key":"10.1016\/j.critrevonc.2026.105339_bib128","doi-asserted-by":"crossref","DOI":"10.1111\/jcmm.18575","article-title":"Generation of B7-H3 isoform regulated by ANXA2\/NSUN2\/YBX1 axis in human glioma","volume":"28","author":"Shen","year":"2024","journal-title":"J. Cell. Mol. Med."},{"key":"10.1016\/j.critrevonc.2026.105339_bib129","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2023.110718","article-title":"Alternative splicing events and function in the tumor microenvironment: new opportunities and challenges","volume":"123","author":"Song","year":"2023","journal-title":"Int. Immunopharmacol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105339_bib130","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1186\/s13059-015-0704-3","article-title":"Enter exitrons","volume":"16","author":"Staiger","year":"2015","journal-title":"Genome Biol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105339_bib131","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1186\/s13059-018-1532-z","article-title":"CRISPR-induced exon skipping is dependent on premature termination codon mutations","volume":"19","author":"Sui","year":"2018","journal-title":"Genome Biol."},{"issue":"12","key":"10.1016\/j.critrevonc.2026.105339_bib132","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1080\/15476286.2019.1659080","article-title":"Modulation of PDCD1 exon 3 splicing","volume":"16","author":"Sun","year":"2019","journal-title":"RNA Biol."},{"issue":"9","key":"10.1016\/j.critrevonc.2026.105339_bib133","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0024751","article-title":"Origination of new immunological functions in the costimulatory molecule B7-H3: the role of exon duplication in evolution of the immune system","volume":"6","author":"Sun","year":"2011","journal-title":"PLoS One"},{"issue":"12","key":"10.1016\/j.critrevonc.2026.105339_bib134","doi-asserted-by":"crossref","first-page":"6294","DOI":"10.4049\/jimmunol.168.12.6294","article-title":"Characterization of mouse and human B7-H3 genes","volume":"168","author":"Sun","year":"2002","journal-title":"J. Immunol."},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105339_bib135","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1292\/jvms.16-0583","article-title":"Gene and protein expression of a soluble form of CTLA-4 in a healthy dog","volume":"79","author":"Tagawa","year":"2017","journal-title":"J. Vet. Med. Sci."},{"issue":"8","key":"10.1016\/j.critrevonc.2026.105339_bib136","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1136\/gutjnl-2022-327133","article-title":"Isoformic PD-1-mediated immunosuppression underlies resistance to PD-1 blockade in hepatocellular carcinoma patients","volume":"72","author":"Tan","year":"2023","journal-title":"Gut"},{"issue":"1-2","key":"10.1016\/j.critrevonc.2026.105339_bib137","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.vetimm.2004.08.008","article-title":"Molecular cloning and mRNA tissue-expression of two isoforms of the ovine costimulatory molecule CD80 (B7-1)","volume":"103","author":"Terzo","year":"2005","journal-title":"Vet. Immunol. Immunopathol."},{"issue":"1-2","key":"10.1016\/j.critrevonc.2026.105339_bib138","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.vetimm.2006.08.003","article-title":"Molecular cloning of multiple forms of the ovine B7-2 (CD86) costimulatory molecule","volume":"114","author":"Terzo","year":"2006","journal-title":"Vet. Immunol. Immunopathol."},{"issue":"11","key":"10.1016\/j.critrevonc.2026.105339_bib139","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1038\/s41416-023-02223-z","article-title":"Soluble CD137 and risk of hepatocellular carcinoma: nested case\u2013control studies in cohorts in Shanghai and Singapore","volume":"128","author":"Thomas","year":"2023","journal-title":"Br. J. Cancer"},{"issue":"14","key":"10.1016\/j.critrevonc.2026.105339_bib140","doi-asserted-by":"crossref","first-page":"4173","DOI":"10.2741\/3521","article-title":"CD137, implications in immunity and potential for therapy","volume":"11","author":"Thum","year":"2009","journal-title":"Front. Biosci."},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105339_bib141","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.it.2008.02.011","article-title":"CTLA-4 trafficking and surface expression","volume":"29","author":"Valk","year":"2008","journal-title":"Trends Immunol."},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105339_bib142","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/S1074-7613(04)00110-4","article-title":"An autoimmune disease-associated CTLA-4 splice variant lacking the B7 binding domain signals negatively in T cells","volume":"20","author":"Vijayakrishnan","year":"2004","journal-title":"Immunity"},{"issue":"12","key":"10.1016\/j.critrevonc.2026.105339_bib143","doi-asserted-by":"crossref","first-page":"4001","DOI":"10.1007\/s00262-023-03534-z","volume":"72","author":"Wahid","year":"2023","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.critrevonc.2026.105339_bib144","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2021.103624","article-title":"Modulating expression of inhibitory and stimulatory immune 'checkpoints' using nanoparticulate-assisted nucleic acid delivery","volume":"73","author":"Walters","year":"2021","journal-title":"EBioMedicine"},{"issue":"12","key":"10.1016\/j.critrevonc.2026.105339_bib145","doi-asserted-by":"crossref","first-page":"8844","DOI":"10.4049\/jimmunol.177.12.8844","article-title":"Aberrant regulation of synovial T cell activation by soluble costimulatory molecules in rheumatoid arthritis","volume":"177","author":"Wan","year":"2006","journal-title":"J. Immunol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105339_bib146","doi-asserted-by":"crossref","first-page":"9114","DOI":"10.1038\/s41467-024-53561-2","article-title":"A splicing isoform of PD-1 promotes tumor progression as a potential immune checkpoint","volume":"15","author":"Wang","year":"2024","journal-title":"Nat. Commun."},{"issue":"10","key":"10.1016\/j.critrevonc.2026.105339_bib147","doi-asserted-by":"crossref","first-page":"2246","DOI":"10.1016\/j.molcel.2021.03.028","article-title":"A pan-cancer transcriptome analysis of exitron splicing identifies novel cancer driver genes and neoepitopes","volume":"81","author":"Wang","year":"2021","journal-title":"Mol. Cell"},{"issue":"11","key":"10.1016\/j.critrevonc.2026.105339_bib148","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1038\/s41419-023-06301-1","article-title":"Inhibition of SF3B1 improves the immune microenvironment through pyroptosis and synergizes with \u03b1PDL1 in ovarian cancer","volume":"14","author":"Wang","year":"2023","journal-title":"Cell Death Dis."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105339_bib149","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1111\/cas.14690","article-title":"Distinct roles of programmed death ligand 1 alternative splicing isoforms in colorectal cancer","volume":"112","author":"Wang","year":"2021","journal-title":"Cancer Sci."},{"key":"10.1016\/j.critrevonc.2026.105339_bib150","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2023.111280","article-title":"An anti-PD-1 antisense oligonucleotide promotes the expression of soluble PD-1 by blocking the interaction between SRSF3 and an exonic splicing enhancer of PD-1 exon 3","volume":"126","author":"Wang","year":"2024","journal-title":"Int. Immunopharmacol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105339_bib151","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1111\/j.1365-2796.2007.01879.x","article-title":"Two SNPs in the promoter region of the CTLA-4 gene affect binding of transcription factors and are associated with human myasthenia gravis","volume":"263","author":"Wang","year":"2008","journal-title":"J. Intern. Med."},{"issue":"10","key":"10.1016\/j.critrevonc.2026.105339_bib152","doi-asserted-by":"crossref","first-page":"729","DOI":"10.2174\/1568009620666200619123725","article-title":"The roles of alternative splicing in tumor-immune cell interactions","volume":"20","author":"Wang","year":"2020","journal-title":"Curr. Cancer Drug Targets"},{"issue":"17","key":"10.1016\/j.critrevonc.2026.105339_bib153","doi-asserted-by":"crossref","first-page":"3441","DOI":"10.1007\/s00018-019-03362-4","article-title":"Modulation of SRSF2 expression reverses the exhaustion of TILs via the epigenetic regulation of immune checkpoint molecules","volume":"77","author":"Wang","year":"2020","journal-title":"Cell. Mol. Life Sci."},{"issue":"7","key":"10.1016\/j.critrevonc.2026.105339_bib154","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1007\/s00011-024-01887-4","article-title":"Surface PD-1 expression in T cells is suppressed by HNRNPK through an exonic splicing silencer on exon 3","volume":"73","author":"Wang","year":"2024","journal-title":"Inflamm. Res."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105339_bib155","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1111\/imm.13793","article-title":"Immunotherapy and the ovarian cancer microenvironment: exploring potential strategies for enhanced treatment efficacy","volume":"173","author":"Wang","year":"2024","journal-title":"Immunology"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105339_bib156","doi-asserted-by":"crossref","DOI":"10.1093\/immadv\/ltaf008","article-title":"CTLA-4-two pathways to anti-tumour immunity?","volume":"5","author":"Ward","year":"2025","journal-title":"Immunother. Adv."},{"issue":"7","key":"10.1016\/j.critrevonc.2026.105339_bib157","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1038\/ni944","article-title":"BTLA is a lymphocyte inhibitory receptor with similarities to CTLA-4 and PD-1","volume":"4","author":"Watanabe","year":"2003","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.critrevonc.2026.105339_bib158","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1146\/annurev-biochem-091719-064225","article-title":"RNA splicing by the spliceosome","volume":"89","author":"Wilkinson","year":"2020","journal-title":"Annu. Rev. Biochem."},{"key":"10.1016\/j.critrevonc.2026.105339_bib159","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.871802","article-title":"Impact of CTLA-4 checkpoint antibodies on ligand binding and transendocytosis","volume":"13","author":"Williams","year":"2022","journal-title":"Front. Immunol."},{"issue":"11","key":"10.1016\/j.critrevonc.2026.105339_bib160","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1038\/s41576-022-00514-4","article-title":"Alternative splicing as a source of phenotypic diversity","volume":"23","author":"Wright","year":"2022","journal-title":"Nat. Rev. Genet."},{"issue":"9","key":"10.1016\/j.critrevonc.2026.105339_bib161","doi-asserted-by":"crossref","first-page":"8193","DOI":"10.3390\/ijms24098193","article-title":"PD-L1 Exon 3 is a hidden switch of its expression and function in oral cancer cells","volume":"24","author":"Yan","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105339_bib162","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1186\/s12864-018-4671-4","article-title":"Indel detection from DNA and RNA sequencing data with transIndel","volume":"19","author":"Yang","year":"2018","journal-title":"BMC Genom."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105339_bib163","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.ccell.2024.11.008","article-title":"Inhibiting intracellular CD28 in cancer cells enhances antitumor immunity and overcomes anti-PD-1 resistance via targeting PD-L1","volume":"43","author":"Yang","year":"2025","journal-title":"Cancer Cell"},{"key":"10.1016\/j.critrevonc.2026.105339_bib164","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.771809","article-title":"CD137 Agonists targeting CD137-mediated negative regulation show enhanced antitumor efficacy in lung cancer","volume":"13","author":"Yi","year":"2022","journal-title":"Front. Immunol."},{"issue":"8","key":"10.1016\/j.critrevonc.2026.105339_bib165","first-page":"815","article-title":"Splicing factor SC35 regulated the expression of B7-H3 in vitro","volume":"28","author":"Yi","year":"2012","journal-title":"Chin. J. Cell. Mol. Immunol."},{"key":"10.1016\/j.critrevonc.2026.105339_bib166","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2025.107713","article-title":"Alternative splicing: a key regulator in T cell response and cancer immunotherapy","volume":"215","author":"Yong","year":"2025","journal-title":"Pharmacol. Res."},{"issue":"9","key":"10.1016\/j.critrevonc.2026.105339_bib167","first-page":"633","article-title":"Reversing T cell exhaustion by converting membrane PD-1 to Its soluble form in jurkat cells; applying the CRISPR\/Cas9 exon skipping strategy","volume":"25","author":"Yousefi-Najafabadi","year":"2023","journal-title":"Cell J."},{"key":"10.1016\/j.critrevonc.2026.105339_bib168","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/bs.pmbts.2019.03.009","article-title":"Tumor mechanisms of resistance to immune attack","volume":"164","author":"Zahavi","year":"2019","journal-title":"Prog. Mol. Biol. Transl. Sci."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105339_bib169","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-010529","article-title":"PD-1(IR2) promotes tumor evasion via deregulating CD8(+) T cell function","volume":"13","author":"Zang","year":"2025","journal-title":"J. Immunother. Cancer"},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105339_bib170","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/s00262-020-02683-9","article-title":"B7-H3 is spliced by SRSF3 in colorectal cancer","volume":"70","author":"Zhang","year":"2021","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.critrevonc.2026.105339_bib171","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.omto.2020.11.001","article-title":"Recombinant oncolytic adenovirus expressing a soluble PVR elicits long-term antitumor immune surveillance","volume":"20","author":"Zhang","year":"2021","journal-title":"Mol. Ther. Oncolytics"},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105339_bib172","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1007\/s13402-021-00633-w","article-title":"Recombinant adenovirus expressing the fusion protein PD1PVR improves CD8(+) T cell-mediated antitumor efficacy with long-term tumor-specific immune surveillance in hepatocellular carcinoma","volume":"44","author":"Zhang","year":"2021","journal-title":"Cell. Oncol. (Dordr. )"},{"key":"10.1016\/j.critrevonc.2026.105339_bib173","doi-asserted-by":"crossref","first-page":"4335","DOI":"10.2147\/JIR.S499403","article-title":"The benefits and safety of monoclonal antibodies: implications for cancer immunotherapy","volume":"18","author":"Zhang","year":"2025","journal-title":"J. Inflamm. Res."},{"issue":"S8","key":"10.1016\/j.critrevonc.2026.105339_bib174","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1002\/cncr.35142","article-title":"Type-I protein arginine methyltransferase inhibition primes anti-programmed cell death protein 1 immunotherapy in triple-negative breast cancer","volume":"130","author":"Zhang","year":"2024","journal-title":"Cancer"},{"issue":"11","key":"10.1016\/j.critrevonc.2026.105339_bib175","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1016\/j.ymthe.2019.07.019","article-title":"Recombinant adenovirus expressing a soluble fusion protein PD-1\/CD137L subverts the suppression of CD8(+) T cells in HCC","volume":"27","author":"Zhang","year":"2019","journal-title":"Mol. Ther."},{"key":"10.1016\/j.critrevonc.2026.105339_bib176","series-title":"PD-L1 alternative splicing. Doctoral thesis","author":"Zhen","year":"2021"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105339_bib177","article-title":"Gingipain regulates isoform switches of PD-L1 in macrophages infected with Porphyromonas gingivalis","volume":"15","author":"Zheng","year":"2025","journal-title":"Sci. Rep."},{"issue":"7","key":"10.1016\/j.critrevonc.2026.105339_bib178","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1038\/mt.2013.63","article-title":"Potentiating functional antigen-specific CD8\u207a T cell immunity by a novel PD1 isoform-based fusion DNA vaccine","volume":"21","author":"Zhou","year":"2013","journal-title":"Mol. Ther."},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105339_bib179","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1158\/2326-6066.CIR-16-0329","article-title":"Soluble PD-L1 as a biomarker in malignant melanoma treated with checkpoint blockade","volume":"5","author":"Zhou","year":"2017","journal-title":"Cancer Immunol. Res."},{"issue":"8","key":"10.1016\/j.critrevonc.2026.105339_bib180","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1093\/abbs\/gmx060","article-title":"Up-regulation of carcinoembryonic antigen-related cell adhesion molecule 1 in gastrointestinal cancer and its clinical relevance","volume":"49","author":"Zhou","year":"2017","journal-title":"Acta Biochim. Biophys. Sin."}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S104084282600226X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S104084282600226X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T07:04:06Z","timestamp":1780038246000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S104084282600226X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":180,"alternative-id":["S104084282600226X"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105339","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Alternative splicing of immune checkpoints: Classifications, mechanisms, and therapeutic implications for overcoming immune checkpoint blockade resistance","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105339","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"105339"}}